Therapy Areas: Devices
BioArctic announces receipt of patent protection in Europe from EPO for a medical device as a part of it's the product candidate SC0806
4 October 2018 -

BioArctic AB (STO:BIOA), a Swedish research-based biopharmaceutical company, announced on Wednesday the issue of a decision by the European Patent Office (EPO) to grant the company's patent application in Europe, EP12815796.3, for a medical device, which is one of the main components in the product candidate SC0806.

This product candidate is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with complete spinal cord injury.

Reportedly, the EPO's decision states that the European patent, EP 2 787 900 B1, will enter into force on 24 October 2018.

According to the company, this patent will provide important protection for medical for treatment of patients with complete spinal cord injury. A corresponding patent has previously been granted in China and during 2018 in Australia, the US and Japan. BioArctic added that it has an active patent strategy covering all major geographic markets, including the US, Japan, China and Europe.

SC0806 is a novel product under development for the treatment for patients with Complete Spinal Cord Injury. The product candidate is currently in an ongoing phase 1/2 clinical trial. The first patient was treated in 2016. The product candidate is a combination of a biodegradable medical device and a drug substance (FGF1) designed to support nerve regeneration across the injured area in the spinal cord.

This product obtained orphan drug designation in 2010 in EU and in 2011 in the US, which gives the company 10 and seven years of market exclusivity in Europe and the US, respectively.

Also, BioArctic has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 643853 to perform a clinical study with SC0806.

BioArctic is focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a potential treatment for Complete Spinal Cord Injury.

Login
Username:

Password: